On December 15th, Shanghai Pharmaceutical Holdings and Sanofi China officially signed a strategic cooperation agreement to engage in extensive and in-depth cooperation across all channels and nationwide in key disease areas, building an end-to-end value chain system from import, distribution to terminal sales. Both parties will maximize drug accessibility through this win-win cooperation and business model, allowing Sanofi's high-quality products to benefit more Chinese people and contribute to the sustainable development of China's local medical and health ecosystem.
Sanofi Greater China President Shi Wang said, We are delighted to see that the strategic cooperation with Shanghai Pharmaceutical Group Co., Ltd. has taken a solid step. Shanghai Pharmaceutical Group Co., Ltd. is a leading pharmaceutical operating enterprise in China, and we believe that through this strong alliance, combined with the core advantages of the two companies, high-quality drugs can be brought to more Chinese patients. Establishing a pharmaceutical innovation business model with local partners is an important part of Sanofi's China innovation and development strategy. We will accelerate the speed of innovation and research and development, Expand the depth and breadth of innovation cooperation, enhance the height of innovation strategy, and achieve a dual focus on innovative product pipelines and innovative business models, so that more innovative, high-quality, and accessible original research drugs and vaccines can benefit the Chinese people and make continuous contributions to the Healthy China 2030 strategy
Li Yongzhong, Executive Director and CEO of Shanghai Pharmaceuticals, stated that, This is one of the largest, widest, and deepest strategic collaborations between the pharmaceutical industry and commerce in recent years. The two sides have worked together to build a new strategic model, greatly improving the efficiency of the pharmaceutical industry chain and promoting deep integration of innovation in the pharmaceutical industry chain. Currently, the fundamental conditions of China's medical system are undergoing significant changes, and there is an urgent need for a new market model to achieve a balance and synergy of 'efficiency+innovation' and better serve the needs of the industry Healthy China strategy. This industrial chain cooperation has achieved a perfect combination of local circulation enterprise commercial efficiency and multinational pharmaceutical enterprise innovation advantages, promoting the cross integration of industrial chain innovation chains through the construction of a new ecosystem, and pushing more valuable drugs to the market and benefiting the people in a more efficient way. We believe that we have the ability to advance this new model of strategic cooperation to a higher level
This cooperation is a comprehensive upgrade of the long-term cooperation between Shanghai Pharmaceutical Holdings and Sanofi China, and has extremely high strategic significance. It is understood that both sides will engage in extensive cooperation across all channels and nationwide in key disease areas, including but not limited to cardiovascular diseases, central nervous system diseases, tumors, etc., around multiple high-quality products of Sanofi. Through strong partnerships with partners such as Sanofi China, Shanghai Pharmaceutical Holdings aims to continuously strengthen the national omnichannel integrated marketing service system and is committed to building the top brand in China's pharmaceutical commercial marketing.